Samsung Biologics Reports Third Quarter 2026 Financial Results
Samsung Biologics announced a 3 trillion won rights offering for strategic investments and capacity expansion amid a raised 20% annual revenue growth target, officials said.
- On Wednesday, Telix Pharmaceuticals Ltd reported third-quarter 2026 results with group revenue growing 19% year-on-year to US$245 million, while Precision Medicine revenue jumped 30% to US$201 million.
- Shares of Telix dropped over 8% to $14.44 on Wednesday following the morning earnings release, despite year-to-date gains of around 27%.
- The Food and Drug Administration approved Pixclara for glioma imaging in September 2026, while Telix advances late-stage clinical trials targeting prostate, brain, and kidney cancer.
- Shareholders will vote in December on the US$1.65 billion merger with Isotope Technologies Munich , designed to create a vertically integrated radiopharmaceutical leader with expanded isotope production capabilities.
- Telix reaffirmed FY26 revenue and other income is expected to exceed US$1 billion, while narrowing its R&D expenditure guidance to US$240 million to US$260 million from the prior range.
19 Articles
19 Articles
Samsung Biologics Q3 net income down 21.2% to $295.2 mil.
Samsung Biologics, the biotech arm of Samsung Group, on Wednesday reported its third-quarter net profit of 391.1 billion won ($295.2 million), down 21.2 percent from a year earlier. The contract development and manufacturing organization (CDMO) service provider, which offers comprehensive development and manufacturing solutions, said in a regulatory filing that it posted 640.1 billion won in operating profit for the quarter, compared with 633.5 …
Samsung Biologics achieved record-breaking quarterly performance in its CDMO business in the third quarter, recording 1.4903 trillion won in revenue and 640.1 billion won in operating profit. This result was driven by the full operation of the Songdo plant and the reflection of revenue from the Rockville facility in the U.S., and the company raised its annual revenue growth forecast to 20%.
(Seoul = Yonhap News) Reporter Shin Seon-mi = Samsung Biologics [207940] reported a consolidated operating profit of 640.1 billion won for the third quarter of this year, up 1% from the same period last year...
Samsung Biologics Reports Third Quarter 2026 Financial Results
Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billionPlant 5 ramp-up and U.S. manufacturing operations contribute to earnings performanceRaised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
